Management of Respiratory Infections

Introduction to Management

Respiratory infections, such as those occurring in chronic obstructive pulmonary disease (COPD), require careful management to prevent exacerbations and improve patient outcomes, as recommended by the American Thoracic Society and the American Academy of Family Physicians 1, 2

Add antibiotics for 5-7 days if increased sputum purulence is present, as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 3
Reserve antibiotic use for cases with increased sputum purulence or other signs of bacterial infection, as recommended by the European Respiratory Society/American Thoracic Society guidelines 4

Consider adding short-course oral corticosteroids (e.g., 30 mg prednisone daily for 5 days) if patient has severe symptoms not responding to initial therapy, a previously documented response to oral corticosteroids, or significant airflow obstruction, according to guidelines from the American Thoracic Society and the American Academy of Family Physicians 1, 2
Use systemic glucocorticoids for 5 days, based on high-quality evidence (Evidence A), and limit to ≤200 mg prednisone equivalents for exacerbation course, as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 3, 2, 5, 6
Systemic corticosteroids can prevent hospitalization for subsequent exacerbations in the first 30 days following the initial exacerbation, as recommended by the American College of Chest Physicians 7

Start bronchodilator therapy with short-acting β2-agonists with or without short-acting anticholinergics, as recommended by the American Thoracic Society 3
Combine the 5-day prednisone course with short-acting bronchodilators, such as short-acting β2-agonists with or without short-acting anticholinergics, as initial treatment, as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 3, 4, 2, 1

Titrate oxygen to maintain SpO2 88-92% if hypoxemia is present, as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 3
Check blood gases within 60 minutes of starting oxygen, and titrate oxygen to maintain SpO2 ≥90% or PaO2 ≥8.0 kPa (60 mmHg), as recommended by the European Respiratory Society 1, 6, 1
Avoid giving oxygen at a rate of FiO2 >28% via Venturi mask or >2 L/min via nasal cannulae until arterial gas tensions are known in patients with COPD history aged 50+ years, as per the British Thoracic Society guidelines 1, 6, 1

Schedule follow-up within 1-2 weeks to assess response, and consider a chest radiograph or possible hospital referral if symptoms persist, as recommended by the British Thoracic Society 1
Use the follow-up visit to review medication technique, assess smoking status, and provide education on exacerbation prevention, as suggested by the European Respiratory Society 1
Schedule follow-up within 3-6 months with repeat spirometry to assess treatment response and disease progression, as recommended by the European Respiratory Society and GOLD 2025, and monitor for decline in FEV1 >50 mL/year, which may indicate need for more aggressive therapy 8, 6, 3

Consider triple inhalation therapy (ICS/LAMA/LABA) for patients with frequent or severe exacerbations and elevated blood eosinophils, patients with COPD and concomitant asthma, or patients with a rapid decline in FEV1 (>50 mL/year), as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 3, 6
Consider phosphodiesterase-4 inhibitors (e.g., roflumilast) and macrolides for patients with chronic bronchitis and history of exacerbations, as recommended by the American Academy of Family Physicians and European Respiratory Society 2, 7
Consider theophylline (delivered as aminophylline IV) as an additional treatment option in patients with life-threatening features, who deteriorate despite standard treatment, or fail to improve rapidly with oxygen, steroids, and bronchodilators, with significant reservations, as recommended by the British Thoracic Society guidelines 9, 10

Consider protection against osteoporosis (calcium and vitamin D, hormone replacement therapy, bisphosphonates) if long-term oral corticosteroids are used, and use inhaled corticosteroids in addition to minimize oral dose when chronic use is necessary, as recommended by the American Academy of Family Physicians and European Respiratory Society 6
Be aware of the numerous side effects of long-term corticosteroid use, including hyperglycemia, osteoporosis, increased risk of infections, muscle weakness, adrenal suppression, and skin thinning and bruising, as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 3, 6